Premium
Prognostic value of cerebrospinal fluid neuron‐specific enolase and S‐100b protein in Guillain‐Barré syndrome
Author(s) -
Mokuno K.,
Kiyosawa K.,
Sugimura K.,
Yasuda T.,
Riku S.,
Murayama T.,
Yanagi T.,
Takahashi A.,
Kato K.
Publication year - 1994
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1994.tb01628.x
Subject(s) - enolase , cerebrospinal fluid , medicine , guillain barre syndrome , gastroenterology , immunoassay , pathology , immunology , immunohistochemistry , antibody
We measured the cerebrospinal fluid (CSF) concentrations of neuron‐specific enolase (NSE) and S‐100b protein (S‐100b) using enzyme immunoassay methods, in 24 patients with Guillain‐Barré syndrome and 46 controls, and examined their prognostic values. Sixteen of 24 patients showed elevated levels (> the mean + 2SD levels of controls) of NSE, S‐100b, or both, and in those with higher NSE or S‐100b levels there was a rather longer duration of disease, whereas 8 patients with the normal levels showed an early recovery. Further, NSE or S‐100b levels were significantly correlated with months to recovery. Thus, NSE and S‐100b in CSF may be useful markers for predicting the outcome of Guillain‐Barré syndrome.